



>> WHAT IS HIALSORB® i.a.?

HIALSORB® i.a. is a one-shot intra-articular injection supplying 20 mg/ml of hyaluronic acid that restores the viscosity and elasticity of the synovial fluid in patients affected by degenerative or mechanical arthropathy which causes pain or reduced mobility.

>> EFFICACY AND SAFETY IN A SINGLE INJECTION

BIOFERMENTATION ORIGIN
HYALURONIC ACID

MOLECULAR WEIGHT
1,000-1,200 kDa

1 SINGLE INTRA-ARTICULAR
ADMINISTRATION

HIGH CONCENTRATION:
60 mg/3 ml (2%)

>> THE EFFECT OF HIALSORB® i.a.

Viscosupplementation effect ¹⁻³

Hyaluronic acid is a polysaccharide naturally present in many human tissues, especially in the synovial fluid of joints, where it acts as a lubricant for cartilage and ligaments, and as a shock absorber.

HIALSORB® i.a. restores the viscosity and elasticity of the synovial fluid and therefore:

REDUCES
PAIN

IMPROVES
MOBILITY


REDUCES
FRICTION

Pharmacological effect ¹⁻⁴

Induces the synthesis of endogenous hyaluronic acid and other components of the extracellular matrix and therefore:

REDUCES
INFLAMMATION

REDUCES
PAIN



>> EXCELLENT TOLERABILITY ⁵

The hyaluronic acid in **HIALSORB® i.a.** is not chemically modified and not cross-linked with other chemical agents.

Through a strict process of biofermentation, we obtain a **highly pure compound which guarantees excellent tolerability.**



ACTIVE INGREDIENT

Hyaluronic acid sodium salt 2%.

INDICATION

HIALSORB® i.a. is a temporary synovial fluid replacement for patients affected by degenerative or mechanical arthropathy which causes pain or reduced mobility.

ADMINISTRATION

Single intra-articular injection.

REGULATORY STATUS

CE marked in the EU as a Medical Device.

PACK

60 ml prefilled disposable syringe.



1. Goldberg VM, Goldberg L. J Pain Res. 2010 May 10;3:51-6.
2. Maheu E, et al. Seminars in Arthritis and Rheumatism 2016.
3. Altman RD, et al. BMC Musculoskeletal Disorders (2015) 16:321.
4. du Souich, P. Pharmacol Ther. 2014 Jun;142(3):362-74
5. Hamburger MI, et al. Semin Arthr Rheum 32(5):296-309.



BIOIBERICA is a biotechnological company that specializes in the research, production and distribution of biomolecules such as Chondroitin sulfate, Glucosamine, Heparin and Hyaluronic acid.

Since 1975, Bioiberica has consolidated its position as an international leader in joint health and chondroprotection thanks to a constant dedication and commitment to science and research.

Vertically integrated, from the active ingredient to the finished product, Bioiberica places all its medical, molecule and market knowledge at its partners disposal for the joint development of the market.